TrialAnnals of hematology2024

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.

Lucía Pérez-Lamas et al.PubMed ↗Publisher ↗

No numbers read from the abstract.